Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Rivus’ fat-trimming therapy nabs $35M to harness our own biology against a host of diseases
Fierce Biotech
Tue, 07/20/21 - 12:27 pm
Rivus Pharmaceuticals
type 2 diabetes
NASH
hypertriglyceridemia
heart failure with preserved ejection fraction
Poxel pivots to different programs, but questions abound over imeglimin
Fierce Biotech
Mon, 07/12/21 - 10:46 am
Poxel
NASH
diabetes
imeglimin
Four New Biotechs Launch to Combat MD, NASH, Parkinson's and More
BioSpace
Wed, 06/23/21 - 10:44 pm
funding
Vita Therapeutics
limb-girdle muscular dystrophy
NuvoAir
Respiratory
Enveda Biosciences
NASH
Parkinson's Disease
ImmuneID
immunology
Terns Pharmaceuticals touts safety data from an ex-Eli Lilly candidate in the hunt for NASH treatment
Endpoints
Tue, 06/15/21 - 11:35 pm
Terns Pharmceuticals
Eli Lilly
FXR agonists
NASH
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Endpoints
Thu, 05/27/21 - 11:06 am
Intercept Pharma
NASH
Ocaliva
FDA
primary biliary cholangitis
NGM’s closely-watched NASH prospect flops, cutting shares in half and spurring R&D rethink
Fierce Biotech
Mon, 05/24/21 - 10:44 am
NGM Biopharmaceuticals
NASH
clinical trials
Gilead, Novo Nordisk push NASH cocktail deeper into the clinic
Fierce Biotech
Thu, 03/18/21 - 10:54 am
Gilead Sciences
Novo Nordisk
NASH
R&D
Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?
Endpoints
Tue, 02/23/21 - 11:14 pm
Intercept Pharma
NASH
Glympse Advances BioSensors for NASH and Other Protease-Mediated Diseases
BioSpace
Wed, 01/6/21 - 11:16 pm
Glympse Bio
biosensors
diagnostics
NASH
Eli Lilly's transpacific bosom buddy Terns bags late-round funding to drive NASH hopefuls through the clinic
Endpoints
Tue, 01/5/21 - 10:03 am
NASH
Terns Pharmaceuticals
Eli Lilly
Longtime Intercept CEO Mark Pruzanski departs as ailing NASH company tries to find its future
Endpoints
Thu, 12/10/20 - 11:19 am
Mark Pruzanski
Pharma CEOs
Intercept Pharma
NASH
Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol
BioSpace
Thu, 11/19/20 - 10:27 am
Viking Therapeutics
NASH
VK2809
Gilead and Novo plot next steps after trial data from NASH combo
Pharmaforum
Mon, 11/16/20 - 10:19 am
Gilead Sciences
Novo Nordisk
NASH
clinical trials
semaglutide
cilofexor
firsocostat
AASLD 2020 – Nash updates from Novo and Inventiva in focus
EP Vantage
Wed, 11/4/20 - 10:09 am
NASH
Novo Nordisk
Gilead Sciences
Inventiva
AASLD
selonsertib
Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow
Endpoints
Fri, 10/30/20 - 10:25 am
Novo Nordisk
earnings
NASH
semaglutide
breakthrough therapy
FDA
Pfizer Q3 cull sees midstage fast-tracked NASH drug axed, with a cancer vaccine and arthritis asset also chopped
Fierce Pharma
Tue, 10/27/20 - 10:44 am
Pfizer
earnings
NASH
arthritis
cancer vaccines
Shedding light on Intercept’s opaque disclosure
EP Vantage
Tue, 10/13/20 - 11:13 am
Intercept Pharma
Ocaliva
NASH
drug safety
Riding a PhII success, a small French biotech lands a rare 'breakthrough' status in NASH
Endpoints
Tue, 10/13/20 - 11:03 am
Inventiva
NASH
France
FDA
breakthrough status
lanifibranor
Gannex received US IND approval for its NASH Drug Candidate ASC42
Pharmaceutical Business Review
Mon, 10/12/20 - 10:05 am
Gannex Pharma
Ascletis Pharmaceuticals
NASH
FDA
ASC42
In another blow to Intercept, the FDA is investigating Ocaliva for potential risk of liver disorder
Endpoints
Fri, 10/9/20 - 10:48 am
FDA
Intercept Pharmaceuticals
Ocaliva
NASH
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »